Lubazodone

Lubazodone (developmental code names YM-992, YM-35995) is an experimental antidepressant which was under development by Yamanouchi for the treatment for major depressive disorder in the late 1990s and early 2000s but was never marketed.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Lubazodone (developmental code names YM-992, YM-35995) is an experimental antidepressant which was under development by Yamanouchi for the treatment for major depressive disorder in the late 1990s and early 2000s but was never marketed. It acts as a serotonin reuptake inhibitor (K i for = 21 nM) and 5-HT 2A receptor antagonist (K i = 86 nM), and hence has the profile of a serotonin antagonist and reuptake inhibitor (SARI).

The drug has good selectivity against a range of other monoamine receptors, with its next highest affinities being for the α 1 -adrenergic receptor (K i = 200 nM) and the 5-HT 2C receptor (K i = 680 nM). Lubazodone is structurally related to trazodone and nefazodone, but is a stronger serotonin reuptake inhibitor and weaker as a 5-HT 2A receptor antagonist in comparison to them and is more balanced in its actions as a SARI.

It reached phase II clinical trials for depression, but development was discontinued in 2001 reportedly due to the "erosion of the market in the United States".

Lubazodone (developmental code names YM-992, YM-35995) is an experimental antidepressant which was under development by Yamanouchi for the treatment for major depressive disorder in the late 1990s and early 2000s but was never marketed. It acts as a serotonin reuptake inhibitor (K i for = 21 nM) and 5-HT 2A receptor antagonist (K i = 86 nM), and hence has the profile of a serotonin antagonist and reuptake inhibitor (SARI).

The drug has good selectivity against a range of other monoamine receptors, with its next highest affinities being for the α 1 -adrenergic receptor (K i = 200 nM) and the 5-HT 2C receptor (K i = 680 nM). Lubazodone is structurally related to trazodone and nefazodone, but is a stronger serotonin reuptake inhibitor and weaker as a 5-HT 2A receptor antagonist in comparison to them and is more balanced in its actions as a SARI.

It reached phase II clinical trials for depression, but development was discontinued in 2001 reportedly due to the "erosion of the market in the United States".

See also

Serotonin antagonist and reuptake inhibitor List of investigational antidepressants

Text derived from https://en.wikipedia.org/w/index.php?oldid=1370553977 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.